Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
Adjuvant
Alum
CAF®01
CD8(+) T cell response
Spray drying
Zinc oxide (ZnO) nanoparticles
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
received:
11
08
2023
revised:
28
10
2023
accepted:
03
11
2023
medline:
5
12
2023
pubmed:
7
11
2023
entrez:
6
11
2023
Statut:
ppublish
Résumé
Most licensed human vaccines are based on liquid dosage forms but have poor storage stability and require continuous and expensive cold-chain storage. In contrast, the use of solid vaccine dosage forms produced by for example spray drying, extends shelf life and eliminates the need for a cold chain. Zinc oxide (ZnO)-based nanoparticles display immunomodulatory properties, but their adjuvant effect as a dry powder formulation is unknown. Here, we show that reconstituted dry powder formulations of ZnO particles containing the model antigen ovalbumin (OVA) induce antigen-specific CD8
Identifiants
pubmed: 37931728
pii: S0378-5173(23)01002-5
doi: 10.1016/j.ijpharm.2023.123581
pii:
doi:
Substances chimiques
Aluminum Hydroxide
5QB0T2IUN0
Ovalbumin
9006-59-1
Zinc Oxide
SOI2LOH54Z
Powders
0
Adjuvants, Immunologic
0
Vaccines
0
Adjuvants, Pharmaceutic
0
Antigens
0
Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123581Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.